Leerink Partnrs Issues Pessimistic Estimate for TMO Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO) – Investment analysts at Leerink Partnrs decreased their Q4 2026 earnings per share estimates for shares of Thermo Fisher Scientific in a report released on Thursday, July 17th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings of $6.95 per share for the quarter, down from their previous estimate of $7.12. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $23.28 per share.

TMO has been the topic of several other reports. Royal Bank Of Canada reduced their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating on the stock in a research report on Thursday, April 24th. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Wednesday, May 21st. Barclays reduced their target price on Thermo Fisher Scientific from $475.00 to $450.00 and set an “equal weight” rating on the stock in a report on Tuesday, June 24th. Argus dropped their price target on Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating on the stock in a research note on Tuesday, April 29th. Finally, Wells Fargo & Company lowered their target price on Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating on the stock in a research report on Thursday, April 24th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $599.30.

Thermo Fisher Scientific Stock Down 2.3%

NYSE:TMO opened at $415.29 on Monday. Thermo Fisher Scientific has a 12-month low of $385.46 and a 12-month high of $627.88. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $156.77 billion, a P/E ratio of 24.36, a P/E/G ratio of 2.21 and a beta of 0.77. The stock’s fifty day simple moving average is $410.38 and its 200-day simple moving average is $472.32.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The business had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.23 billion. During the same period in the prior year, the firm posted $5.11 EPS. Thermo Fisher Scientific’s quarterly revenue was up .2% compared to the same quarter last year.

Hedge Funds Weigh In On Thermo Fisher Scientific

Large investors have recently added to or reduced their stakes in the business. Brighton Jones LLC lifted its position in shares of Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after buying an additional 988 shares in the last quarter. Revolve Wealth Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares during the period. Bank Pictet & Cie Europe AG raised its holdings in shares of Thermo Fisher Scientific by 0.3% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 153,157 shares of the medical research company’s stock worth $79,677,000 after purchasing an additional 461 shares during the period. Proficio Capital Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 32.1% in the 4th quarter. Proficio Capital Partners LLC now owns 1,466 shares of the medical research company’s stock worth $763,000 after purchasing an additional 356 shares during the period. Finally, Madison Investment Advisors LLC bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $270,000. Institutional investors own 89.23% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president directly owned 23,167 shares in the company, valued at $9,960,188.31. This trade represents a 1.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.41%. Thermo Fisher Scientific’s payout ratio is currently 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.